|
|
 |
|
Viewing report
|
|
|
|
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Bioseeker, Nov 2007, Pages: 380
In this triple analysis report we have analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Breast- and Prostate cancer, which are all subjects to an extensive number of innovative drug candidates. This extensive 380+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Breast- and Prostate cancer. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
There are currently more than 400 antibody based drugs in development for the treatment of cancer. We have surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.
Drug targets and their associated antibodies have been analyzed by us according to:
- 34 Different molecular functions of target
- 13 Major signaling pathways
- Cancer stem cells
- Conjugated antibodies
- Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
- 31 Targeted cancer indications
- Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
- Antibody therapeutic companies
In breast cancer we have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. As a treatment for breast cancer hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been iniated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.
In prostate cancer we have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Two of the most successful strategies are apoptosis inducers and cell based vaccines. Three out of 10 late stage candidates are apoptosis inducers. Cell based vaccines has been tried for some time but has so far failed to generate substantial improvements.
Breast and Prostate Cancer Highlights
- Thorough examination of status and impact of several novel drugs in development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.
- Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast- and prostate cancer R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities associated with breast- and prostate cancer therapy
Customers who bought this item also bought
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Novel Targets in Drug Discovery
Kinases: Advanced Strategies and Multiple Targets for Drug Discovery
Antibody Drug Target Atlas in Oncology
Transmembrane Transporters: High Sales, High Potential as Drug Targets
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
Global Pipeline Review & Analysis of Hematological Malignancies
Proteases as Drug Targets: Technologies and Opportunities for Drug Discovery
|
|
|
|
